REGENXBIO Reports Positive Data From Phase I/II/III CAMPSIITE Trial Of RGX-121

REGENXBIO Inc. (RGNX) announced positive Phase I/II/III CAMPSIITE trial data for RGX-121, its gene therapy for Mucopolysaccharidosis Type II (Hunter syndrome), confirming the primary endpoint of CSF HS D2S6 reduction at week 16 was met. These longer-term pivotal results have been submitted to the FDA in support of the ongoing Biologics License Application review. A regulatory decision on RGX-121 is anticipated by February 8, 2026, marking a significant milestone for RGNX's pipeline and potential market entry.

Analysis

REGENXBIO Inc. has announced a significant clinical advancement, reporting positive data from the Phase I/II/III CAMPSIITE trial for its gene therapy candidate, RGX-121, for Mucopolysaccharidosis Type II (Hunter syndrome). The trial successfully met its primary endpoint, which measured the reduction of CSF HS D2S6 at week 16. This pivotal data has been submitted to the U.S. Food and Drug Administration (FDA) in response to an information request as part of the ongoing Biologics License Application (BLA) review. This development materially strengthens the regulatory submission for RGX-121 and establishes a clear, long-term catalyst for the company, with the FDA expected to render a decision on the application by February 8, 2026.

Key Decisions for Investors

• The positive pivotal data significantly de-risks the RGX-121 program, supporting a bullish outlook on this key pipeline asset for REGENXBIO.
• Investors should mark February 8, 2026, as a critical binary event date for the potential approval of RGX-121, making RGNX a long-term catalyst-driven holding.
• While this news is strongly positive, the extended timeline to the FDA decision introduces holding risk; therefore, monitoring the company's capital position and any interim regulatory communications will be crucial.